RELAX-AHF: Poor diuretic response associated with worse clinical outcomes
Serelaxin has neutral effect on diuretic response
Heart Failure (HF)
Date: 17 May 2014
Athens, 17 May 2014:
Poor diuretic response is associated with worse in-hospital and post-discharge clinical outcomes, results of the RELAX-AHF trial reveal. The study also found that serelaxin has a neutral effect on diuretic response.
These novel data from the RELAX-AHF trial were presented by lead author Professor Adriaan A. Voors at the Heart Failure Congress 2014, held 17-20 May in Athens, Greece. The Congress is the main annual meeting of the Heart Failure Association of the European Society of Cardiology.
RELAX-AHF was a double blind, placebo-controlled trial of 1161 patients admitted to hospital with acute heart failure. Patients were randomised to receive 48-hour infusions of placebo or serelaxin (30µg/kg per day) within 16 hours from presentation. Primary analysis of the study showed that serelaxin reduced dyspnoea and decreased 180 day mortality.1
The current sub-study, presented for the first time today, had two aims. The first was to confirm preliminary findings of the PROTECT trial, which found that poor diuretic response is a serious clinical problem. 2 The second was to investigate whether the beneficial effects of serelaxin discovered in the primary analysis were related to improvement of the diuretic response.
Diuretic response was defined as kilograms of weight loss per 40mg of the loop diuretic furosemide. Professor Voors said: “Congestion is the main problem in patients with acute decompensated heart failure and we give them loop diuretics to get rid of the excess fluid. Patients who respond to the loop diuretic have diuresis and lose weight. But a substantial proportion do not respond to the diuretic, do not diurese and do not lose weight.”
He added: “Diuretic response could be measured by urinary output but when patients no longer need a catheter it is difficult to capture how much fluid they have lost. We therefore used weight loss as a more objective and reliable measurement of diuretic response. The more weight patients lost per mg of furosemide given, the better their diuretic response.”
The study found that diuretic response was an important clinical problem, confirming preliminary results from the PROTECT trial. Patients with a poor diuretic response had less dyspnoea relief (p=0.0001) and a higher risk of cardiovascular death or rehospitalisation for heart failure or renal failure through day 60 (p<0.004). Poor diuretic response was not associated with increased 180-day cardiovascular mortality (p=0.546).
Professor Voors said: “The most important message from this substudy is that if patients are hospitalised for acute heart failure and do not respond well to their diuretic then they are in trouble. Their recovery in hospital is likely to be worse and when they are sent home there is a good chance that they will be rehospitalised again or even die.”
The next question was whether serelaxin influenced patients’ response to diuretics. The researchers found that serelaxin had no effect on diuretic response. Patients in the serelaxin group improved clinically and were given fewer diuretics but they lost less weight than the placebo group.
Professor Voors said: “Patients felt better with serelaxin and so physicians gave them less diuretics. But these patients did not diurese more, so the overall effect of serelaxin on diuretic response was neutral. We will continue to look for the mechanisms by which serelaxin exerts its positive effects. The current study shows that the beneficial effects of serelaxin are not through improvement of diuretic response. We have already shown that serelaxin prevents the organ damage that occurs during an episode of acute heart failure 3 and we will continue to investigate other modes of action.”
He concluded: “The major finding from this substudy of the RELAX-AHF trial is that diuretic resistance is a clinical problem that leads to worse in-hospital and early post-discharge clinical outcomes in patients with acute heart failure. More insights are needed into the problem of poor diuretic response so that better therapies can be found to improve the diuretic response and improve clinical outcomes.”
Authors: ESC Press Office
Tel: +33 6 22 83 45 76
Notes to editor
1 Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M; RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013 Jan 5;381(9860):29-39. doi: 10.1016/S0140-6736(12)61855-8. Epub 2012 Nov 7
About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
About the Heart Failure Association (HFA)
The Heart Failure Association (HFA) is a registered branch of the ESC. Its aim is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
For practical information about heart failure aimed at patients, families and caregivers, visit the HFA’s Heart Failure Matters website.
Did you want to tweet about our congress? - if you do, please use the official #heartfailure2014 hashtag! Thank you
Information for journalists attending Heart Failure 2014
- If you have any questions or requests regarding interview opportunities, please contact:
ESC Press Office
Tel: +33 6 22 83 45 76 (off site support number)
- Heart Failure 2014 takes place in Athens, Greece, from 17-20 May 2014 at the MAICC Congress Center.
- Look here for the current final programme.
- For full details of a session, have a look at the Scientific Programme & Planner
- On-site Press registration process:
- Free registration applies to press representatives upon receipt of valid credentials and a fully completed embargo form.
- Credential: either your ID press card or letter of assignment with proof of 3 published articles
- Press registration is not available to Industry or its Public Relations representatives, event management, marketing or communications representatives
- The decision of the ESC Press Office is final regarding all press registration requests.
- When your registration as press will be validated you will be given a press badge and the press kit.
- The press working area is located in front of the registration desks. It features free wifi and a printer linked to a computer.
2 Valente MA, Voors AA, Damman K, Van Veldhuisen DJ, Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JG, Givertz MM, Bloomfield DM, Fiuzat M, Dittrich HC, Hillege HL. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J. 2014 Feb 28.
3 Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR;RELAX-AHF Investigators. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol. 2013 Jan 15;61(2):196-206. doi: 10.1016/j.jacc.2012.11.005.
The references of this press releases are available at firstname.lastname@example.org.